ATE58062T1 - Polyoxypropylen-polyoxyaethylen blockcopolymer enthaltende adjuvantien und ihre verwendung in impfstoffen. - Google Patents

Polyoxypropylen-polyoxyaethylen blockcopolymer enthaltende adjuvantien und ihre verwendung in impfstoffen.

Info

Publication number: ATE58062T1
Authority: AT; Austria
Prior art keywords: amount; volume; polyoxypropylene; polyoxyaethylene; vaccines
Prior art date: 1983-08-22

Application number

AT84305687T

Other languages

English (en)

Inventor

Anthony Clifford Allison

Noelene Elva Byars

Original Assignee

Syntex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-08-22

Filing date

1984-08-21

Publication date

1990-11-15

1984-08-21 Application filed by Syntex Inc filed Critical Syntex Inc

1990-11-15 Application granted granted Critical

1990-11-15 Publication of ATE58062T1 publication Critical patent/ATE58062T1/de

Links

239000002671 adjuvant Substances 0.000 title abstract 2
229960005486 vaccine Drugs 0.000 title abstract 2
229920001400 block copolymer Polymers 0.000 title 1
231100000252 nontoxic Toxicity 0.000 abstract 2
230000003000 nontoxic effect Effects 0.000 abstract 2
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 abstract 1
102000002068 Glycopeptides Human genes 0.000 abstract 1
108010015899 Glycopeptides Proteins 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract 1
230000002434 immunopotentiative effect Effects 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1
239000011780 sodium chloride Substances 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
- Y10S516/01—Wetting, emulsifying, dispersing, or stabilizing agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
- Y10S516/01—Wetting, emulsifying, dispersing, or stabilizing agents
- Y10S516/02—Organic and inorganic agents containing, except water
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Dispersion Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Mycology (AREA)
Microbiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Compositions Of Macromolecular Compounds (AREA)
Cosmetics (AREA)
Polyethers (AREA)
Medicinal Preparation (AREA)
Lubricants (AREA)

AT84305687T 1983-08-22 1984-08-21 Polyoxypropylen-polyoxyaethylen blockcopolymer enthaltende adjuvantien und ihre verwendung in impfstoffen. ATE58062T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/525,190 US4606918A (en)	1983-08-22	1983-08-22	Polyoxypropylene-polyoxyethylene block polymer based adjuvants
EP84305687A EP0135376B1 (de)	1983-08-22	1984-08-21	Polyoxypropylen-Polyoxyäthylen Blockcopolymer enthaltende Adjuvantien und ihre Verwendung in Impfstoffen

Publications (1)

Publication Number	Publication Date
ATE58062T1 true ATE58062T1 (de)	1990-11-15

Family

ID=24092296

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT84305687T ATE58062T1 (de)	1983-08-22	1984-08-21	Polyoxypropylen-polyoxyaethylen blockcopolymer enthaltende adjuvantien und ihre verwendung in impfstoffen.

Country Status (14)

Country	Link
US (1)	US4606918A (de)
EP (1)	EP0135376B1 (de)
JP (2)	JPH0617314B2 (de)
AT (1)	ATE58062T1 (de)
AU (1)	AU578907B2 (de)
CA (1)	CA1236017A (de)
DE (1)	DE3483553D1 (de)
DK (1)	DK167173B1 (de)
HK (1)	HK82392A (de)
IE (1)	IE58035B1 (de)
IL (1)	IL72740A (de)
NZ (1)	NZ209293A (de)
PH (1)	PH21112A (de)
ZA (1)	ZA846504B (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4606918A (en) *	1983-08-22	1986-08-19	Syntex (U.S.A.) Inc.	Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4933179A (en) *	1983-08-22	1990-06-12	Syntex (U.S.A.) Inc.	Feline leukemia virus antigen vaccines
US4857318A (en) *	1983-11-07	1989-08-15	Syntex (U.S.A.) Inc.	Bordetella bronchiseptica pilus subunit protein vaccine effective against bordetella pertussis
US5171568A (en) *	1984-04-06	1992-12-15	Chiron Corporation	Recombinant herpes simplex gb-gd vaccine
US5244792A (en) *	1984-04-06	1993-09-14	Chiron Corporation	Expression of recombinant glyoprotein B from herpes simplex virus
US4713240A (en) *	1985-04-04	1987-12-15	Research Corporation	Vaccines based on insoluble supports
AU6073386A (en) *	1985-07-30	1987-02-05	International Minerals & Chemical Corporation	Stabilization of growth promoting hormones
US4803070A (en) *	1986-04-15	1989-02-07	Ribi Immunochem Research Inc.	Immunological emulsion adjuvants for polysaccharide vaccines
US4877611A (en) *	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
US4806352A (en) *	1986-04-15	1989-02-21	Ribi Immunochem Research Inc.	Immunological lipid emulsion adjuvant
US5648071A (en) *	1986-05-15	1997-07-15	Emory University	Method of treating tumors
US5554372A (en) *	1986-09-22	1996-09-10	Emory University	Methods and vaccines comprising surface-active copolymers
US5811088A (en) *	1987-02-20	1998-09-22	Emory University	Antiinfective compounds and methods of use
US5674911A (en) *	1987-02-20	1997-10-07	Cytrx Corporation	Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
EP0283085B1 (de) *	1987-03-17	1992-11-11	Akzo N.V.	Adjuvanzienmischung
US5565209A (en) *	1987-03-17	1996-10-15	Akzo Nobel N.V.	Adjuvant mixture
US5376369A (en) *	1987-11-03	1994-12-27	Syntex (U.S.A.) Inc.	Vaccine adjuvant
ATE149091T1 (de) *	1987-11-03	1997-03-15	Syntex Inc	Einen tetra-polyol enthaltendes impfstoff- adjuvans
EP0318081B1 (de) *	1987-11-27	1991-07-24	Akzo N.V.	Stabilisierung von Antikörpern
US5149529A (en) *	1988-04-08	1992-09-22	Board Of Trustees Of Leland Chiron Corporation	Compositions and treatment for herpes simplex
JPH0832638B2 (ja) *	1989-05-25	1996-03-29	カイロンコーポレイション	サブミクロン油滴乳剤を含んで成るアジュバント製剤
NZ238731A (en) *	1990-06-27	1996-02-27	Univ Emory	Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide
JP2502234B2 (ja) *	1990-06-29	1996-05-29	カイロンコーポレイション	リポソ―ム含有ワクチン組成物
FR2664813B1 (fr) *	1990-07-18	1995-01-13	Vacsyn France Sa	Compositions a base de substances hydrophobes, solubilisables dans un solvant aqueux, leur procede d'obtention, et leurs utilisations notamment dans le domaine pharmaceutique.
FR2672496B3 (fr) *	1990-07-18	1993-05-28	Vacsyn France Sa	Compositions a base de substances hydrophobes, solubilisables dans un solvant aqueux, leur procede d'obtention, et leurs utilisations notamment dans le domaine pharmaceutique.
US20020123476A1 (en) *	1991-03-19	2002-09-05	Emanuele R. Martin	Therapeutic delivery compositions and methods of use thereof
IE920860A1 (en) *	1991-03-19	1992-09-23	Cytrx Corp	Polyoxypropylene/polyoxyethylene copolymers with improved¹biological activity
US6933286B2 (en)	1991-03-19	2005-08-23	R. Martin Emanuele	Therapeutic delivery compositions and methods of use thereof
US5696298A (en) *	1991-03-19	1997-12-09	Cytrx Corporation	Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US7202225B1 (en)	1993-10-15	2007-04-10	Emanuele R Martin	Therapeutic delivery compositions and methods of use thereof
USRE38558E1 (en)	1991-03-19	2004-07-20	Cytrx Corporation	Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5622649A (en) *	1991-06-27	1997-04-22	Emory University	Multiple emulsions and methods of preparation
ES2116340T3 (es) *	1991-06-27	1998-07-16	Univ Emory	Emulsiones multiples y metodos de preparacion.
US6197311B1 (en)	1991-07-25	2001-03-06	Idec Pharmaceuticals Corporation	Induction of cytotoxic T-lymphocyte responses
US5342612A (en) *	1991-12-20	1994-08-30	American Cyanamid Company	Compositions for the treatment of mammalian diseases
ZA929870B (en) *	1991-12-23	1993-08-18	Duphar Int Res	Adjuvants
AU3361093A (en) *	1992-01-20	1993-08-03	Peptech (Uk) Limited	Use of muramyl peptides for enhancing animal production
FR2702373B1 (fr) *	1993-03-08	1996-06-07	Rhone Merieux	Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
US5961970A (en) *	1993-10-29	1999-10-05	Pharmos Corporation	Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) *	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
DE69518316T2 (de) *	1994-05-10	2001-03-29	American Home Products Corp., Madison	Modifizierter,verbesserter,lebender brsv impfstoff
US6156319A (en) *	1994-07-25	2000-12-05	The Trustees Of The University Of Pennsylvania	Soluble herpesvirus glycoprotein complex vaccine
EP1181937A3 (de)	1994-08-09	2004-02-04	Cytrx Corporation	Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
EP0750907B1 (de) *	1995-06-30	2002-03-20	American Cyanamid Company	Stabile Makrolide und Makrolide Imptstoff-Zusammensetzungen
EP0781559B1 (de) *	1995-11-30	2007-02-07	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute	Öladjuvierter Impfstoff und Verfahren zu seiner Herstellung
ATE252316T1 (de)	1996-06-05	2003-11-15	Ashmont Holdings Ltd	Injizierbare zusammensetzungen
SK138199A3 (en) *	1997-04-08	2000-06-12	Merck & Co Inc	Human papillomavirus antigen formulation and method for stabilizing a population of virus-like purified particles, derived from protein l1 or protein l1 and l2 of human papillomavirus
AU769539B2 (en)	1999-01-29	2004-01-29	Zoetis Services Llc	Adjuvants for use in vaccines
ATE403436T1 (de) *	1999-03-24	2008-08-15	Secr Defence	Polykationische karbohydrate als immunostimulierende mittel in impstoffen
SE9902364D0 (sv) *	1999-06-21	1999-06-21	Astra Ab	New process
MY129765A (en) *	2000-12-19	2007-04-30	Wyeth Corp	Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) *	2000-12-19	2006-03-28	Wyeth	Mycoplasma hyopneumoniae bacterin vaccine
AU2004262506A1 (en)	2003-02-28	2005-02-17	National Institutes Of Health	Compositions, methods and kits relating to poxvirus subunit vaccines
PL1613346T3 (pl) *	2003-04-04	2013-03-29	Zoetis Services Llc	Poddane mikrofluidyzacji emulsje typu olej w wodzie i kompozycje szczepionek
EP2332569A3 (de) *	2004-06-25	2011-09-14	ID Biomedical Corporation of Quebec	Zusammensetzungen und Verfahren zur Behandlung von neurologischen Erkrankungen
EP1781338A4 (de) *	2004-07-19	2010-02-10	Baylor College Medicine	Modulierung von zytokin-signalisierungsregulatoren und anwendungen für die immuntherapie
US7868159B2 (en) *	2005-06-23	2011-01-11	Baylor College Of Medicine	Modulation of negative immune regulators and applications for immunotherapy
BRPI0708842A2 (pt) *	2006-03-28	2011-06-14	Gelesis Inc	uso de materiais polimÉricos com outras substÂncias para aumento do desempenho
WO2008116347A1 (en)	2007-03-26	2008-10-02	General Regeneratives Limited	Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies
JP5334462B2 (ja)	2007-06-11	2013-11-06	花王株式会社	脂肪酸エステルの製造法
EP2222344A4 (de) *	2007-11-30	2012-11-07	Baylor College Medicine	Impfstoffzusammensetzungen mit dendritischen zellen und ihre verwendung
EP2722056A1 (de)	2007-12-03	2014-04-23	President and Fellows of Harvard College	CT062, ein Chlamydia-Antigene
US9808504B2 (en)	2009-09-22	2017-11-07	Yale University	Immunogenic epitopes as targets for universal cancer vaccines
WO2011133227A2 (en)	2010-04-23	2011-10-27	Ancora Pharmaceuticals Inc.	Synthetic oligosaccharides for staphyloccocus vaccine
WO2011137181A1 (en)	2010-04-27	2011-11-03	Ancora Pharmaceuticals Inc.	Synthetic oligosaccharides for moraxella vaccine
WO2011149778A1 (en)	2010-05-26	2011-12-01	Ancora Pharmaceuticals Inc.	Synthetic oligosaccharides for neisseria meningitis vaccine
EP2399928B1 (de)	2010-06-23	2017-11-08	Deutsches Krebsforschungszentrum	Spezifische TT-Virus-Sequenzen und chimäre DNA-Moleküle von TT-Virus-Wirtszellen zur Verwendung bei Diagnose, Vorbeugung und Behandlung von Krebs und Autoimmunität
JP6069212B2 (ja)	2010-12-02	2017-02-01	ビオノールイミュノエーエスＢｉｏｎｏｒＩｍｍｕｎｏＡｓ	ペプチド骨格設計
JP6294076B2 (ja)	2011-01-06	2018-03-14	ビオノールイミュノエーエスＢｉｏｎｏｒＩｍｍｕｎｏＡｓ	多量体ペプチド
CA2846486C (en)	2011-07-12	2019-08-20	Philadelphia Health & Education Corporation	Novel clostridium difficile dna vaccine
US9120859B2 (en)	2012-04-04	2015-09-01	Zoetis Services Llc	Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk)	2012-04-04	2017-06-26	Зоетіс Сервісіз Ллс	Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk)	2012-04-04	2017-06-26	Зоетіс Сервісіз Ллс	Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
KR20150018870A (ko)	2012-06-06	2015-02-24	바이오노르 이뮤노 에이에스	면역원 및 투여 반응제로서 사용하기 위한 바이러스 단백질로부터 유래하는 펩타이드
JP5971652B2 (ja)	2012-10-09	2016-08-17	三菱重工業株式会社	石炭不活性化処理装置
WO2015116178A1 (en)	2014-01-31	2015-08-06	Thomas Jefferson University	Fusion proteins for modulating regulatory and effector t cells
US9834610B2 (en)	2013-01-31	2017-12-05	Thomas Jefferson University	Fusion proteins for modulating regulatory and effector T cells
EP2868751A1 (de)	2013-10-30	2015-05-06	Deutsches Krebsforschungszentrum	HCBI-Sequenzen als früher Marker für die zukünftige Entwicklung von Krebs und Erkrankungen des zentralen Nervensystems, und als Ziel zur Behandlung und Prävention von Krebs
EP2966176A1 (de)	2014-07-10	2016-01-13	Deutsches Krebsforschungszentrum	HCBIO-, MSBI-, MSSI- und CMI-Sequenzen als frühe Marker für die zukünftige Entwicklung von Krebs und Erkrankungen des ZNS und als Ziel zur Behandlung und Prävention dieser Erkrankungen
WO2020140007A1 (en)	2018-12-28	2020-07-02	University Of Rochester	Gene therapy for best1 dominant mutations
EP3686289A1 (de)	2019-01-24	2020-07-29	Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts	Cmi-sequenzen als frühmarker für die zukünftige entwicklung von krebs, atherosklerose, diabetes und erkrankungen des zns und als ziel für die behandlung und prävention dieser erkrankungen
US20230109142A1 (en)	2020-02-14	2023-04-06	Immunor As	Corona virus vaccine
WO2025096754A1 (en)	2023-10-31	2025-05-08	Musc Foundation For Research Development	The use of enolase inhibitor pomhex for treatment of fibrosis
WO2026015821A1 (en)	2024-07-12	2026-01-15	University Of Rochester	Antibiotic alkaloid and methods of generating and use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2674619A (en) *	1953-10-19	1954-04-06	Wyandotte Chemicals Corp	Polyoxyalkylene compounds
US3867521A (en) *	1970-08-26	1975-02-18	Scherer Corp R P	Method for absorption of drugs
BE795516A (fr) *	1972-02-17	1973-08-16	Ciba Geigy	Preparations de peptides huileuses et injectables et procede pour leur preparation
US3869546A (en) *	1972-12-22	1975-03-04	Cutter Lab	Adjuvant compositions and medicinal mixtures comprising them
US4186194A (en) *	1973-10-23	1980-01-29	Agence Nationale De Valorisation De La Recherche (Anvar)	Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
US4370265A (en) *	1974-10-22	1983-01-25	Agence Nationale De Valorisation	Water soluble agents effective as immunological adjuvants for stimulating in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
IL48325A (en) *	1974-10-22	1979-05-31	Anvar	Immunological-free adjuvant compositions containing n-acetyl muramyl-alanyl-d-isoglutamine or n-acetyl-muramyl-l-alanyl-d-glutamicn acid
US4148869A (en) *	1975-03-06	1979-04-10	Baxter Travenol Laboratories, Inc.	Immunological reagent and method of using same
FR2313078A1 (fr) *	1975-02-07	1976-12-31	Anvar	Composition a base d'huile vegetale metabolisable et d'eau, utilisable notamment pour la constitution de preparations adjuvantes, ces preparations adjuvantes et leur procede d'obtention
US4082736A (en) *	1976-04-26	1978-04-04	Syntex (U.S.A.) Inc.	Novel immunological adjuvant compounds and methods of preparation thereof
US4082735A (en) *	1976-04-26	1978-04-04	Syntex (U.S.A.) Inc.	Novel immunological adjuvant compounds and methods of preparation thereof
GB1563561A (en) *	1976-06-23	1980-03-26	Daiichi Seiyaku Co	Muramyldipeptide derivatives and process for the preparation thereof
FR2358159A1 (fr) *	1976-07-16	1978-02-10	Anvar	Le diamide de l'acide 2-(2-acetamido-2-deoxy-3 - o-d-glucopyranosyl) - d-propionyl-l-alanyl-d-glutamique et medicaments le contenant
FR2368282A1 (fr) *	1976-10-22	1978-05-19	Anvar	Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine
FR2428050A1 (fr) *	1978-06-05	1980-01-04	Anvar	Oligomeres de composes du type muramyl-peptide et medicaments les contenant
JPS5543030A (en) *	1978-09-21	1980-03-26	Dai Ichi Seiyaku Co Ltd	Prophylactic and remedy for microbial infection disease
FR2449697A1 (fr) *	1979-02-20	1980-09-19	Anvar	Nouveaux muramyl-peptides substitues sur un azote peptidique et medicaments les contenant
JPS55111499A (en) *	1979-02-21	1980-08-28	Takeda Chem Ind Ltd	Glucosamine derivative and its preparation
CA1185237A (en) *	1979-02-28	1985-04-09	Yuichi Yamamura	6-deoxyglucosamine-peptide derivatives, their production and use
US4384974A (en) *	1979-07-27	1983-05-24	Revlon, Inc.	Stable water-in-oil emulsions
FI803077A7 (fi) *	1979-10-12	1981-04-13	Ciba Geigy Ag	Foerfarande foer framstaellning av myramylpeptider
US4409209A (en) *	1979-10-12	1983-10-11	Ciba-Geigy Corporation	Novel phosphorylmuramyl peptides and processes for the manufacture thereof
US4406889A (en) *	1980-02-15	1983-09-27	Ciba-Geigy Corporation	Derivatives of aldohexoses, intermediates, processes for their manufacture, preparations containing such compounds, and their use
GR78246B (de) *	1981-01-23	1984-09-26	Ciba Geigy Ag
US4397870A (en) *	1982-07-27	1983-08-09	The University Of Pennsylvania	Process for prolonging retention of emulsion particles in the bloodstream
US4606918A (en) *	1983-08-22	1986-08-19	Syntex (U.S.A.) Inc.	Polyoxypropylene-polyoxyethylene block polymer based adjuvants

1983
- 1983-08-22 US US06/525,190 patent/US4606918A/en not_active Expired - Lifetime
1984
- 1984-08-20 PH PH31121A patent/PH21112A/en unknown
- 1984-08-21 ZA ZA846504A patent/ZA846504B/xx unknown
- 1984-08-21 JP JP59174861A patent/JPH0617314B2/ja not_active Expired - Lifetime
- 1984-08-21 NZ NZ209293A patent/NZ209293A/xx unknown
- 1984-08-21 IL IL72740A patent/IL72740A/xx not_active IP Right Cessation
- 1984-08-21 AU AU32251/84A patent/AU578907B2/en not_active Expired
- 1984-08-21 CA CA000461465A patent/CA1236017A/en not_active Expired
- 1984-08-21 DK DK400684A patent/DK167173B1/da not_active IP Right Cessation
- 1984-08-21 EP EP84305687A patent/EP0135376B1/de not_active Expired - Lifetime
- 1984-08-21 DE DE8484305687T patent/DE3483553D1/de not_active Expired - Lifetime
- 1984-08-21 AT AT84305687T patent/ATE58062T1/de not_active IP Right Cessation
- 1984-08-21 IE IE214884A patent/IE58035B1/en not_active IP Right Cessation
1992
- 1992-10-22 HK HK823/92A patent/HK82392A/en not_active IP Right Cessation
1993
- 1993-08-17 JP JP5203231A patent/JP2557603B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
IE58035B1 (en)	1993-06-16
IL72740A0 (en)	1984-11-30
EP0135376B1 (de)	1990-11-07
IL72740A (en)	1988-02-29
AU578907B2 (en)	1988-11-10
DK400684A (da)	1985-02-23
US4606918A (en)	1986-08-19
IE842148L (en)	1985-02-22
JP2557603B2 (ja)	1996-11-27
JPH0665097A (ja)	1994-03-08
EP0135376A2 (de)	1985-03-27
HK82392A (en)	1992-10-30
AU3225184A (en)	1985-02-28
JPS60105630A (ja)	1985-06-11
ZA846504B (en)	1986-03-26
JPH0617314B2 (ja)	1994-03-09
CA1236017A (en)	1988-05-03
NZ209293A (en)	1988-10-28
EP0135376A3 (en)	1986-12-30
DK400684D0 (da)	1984-08-21
DK167173B1 (da)	1993-09-13
DE3483553D1 (de)	1990-12-13
PH21112A (en)	1987-07-16

Legal Events

Date	Code	Title	Description
1991-07-15	UEP	Publication of translation of european patent specification
2004-11-15	EELA	Cancelled due to lapse of time

Publication	Publication Date	Title
ATE58062T1 (de)	1990-11-15	Polyoxypropylen-polyoxyaethylen blockcopolymer enthaltende adjuvantien und ihre verwendung in impfstoffen.
DK1140165T3 (da)	2009-02-16	Fordbedrede adjuvanssammensætninger baseret på saponin og dermed tilhörende metoder
IE44190L (en)	1977-06-10	Glucosamine derivatives
KR900012630A (ko)	1990-09-01	보조제로서 토콜을 함유한 백신 및 그것의 제조방법
ATE103180T1 (de)	1994-04-15	Impfstoff-zubereitung.
SE8603582D0 (sv)	1986-08-26	Komposition innehallande l-dopa
DK0558584T3 (da)	1995-10-02	Geldannende, flydende diætetisk fiberpræparat
DK273384A (da)	1984-12-07	Levende adjuvansholdige vacciner og fremgangsmaader til fremstilling af saadanne vacciner
ATE149091T1 (de)	1997-03-15	Einen tetra-polyol enthaltendes impfstoff- adjuvans
GB1546027A (en)	1979-05-16	Stabilised thymosin fraction and a method for the preparation of same
EP0296504A3 (de)	1989-05-31	Polycarbonat
Eickhoff et al.	1969	Protection against Hong Kong influenza by adjuvant vaccine containing A2/Ann Arbor/67
ATE18007T1 (de)	1986-03-15	Hepatitisimpfstoff.
JPS56166956A (en)	1981-12-22	Liquid separating agent
JPS56145203A (en)	1981-11-11	Plant growth regulating agent composition
Alfonso Barajas-Rojas et al.	1993	A study of association between elisa response to infectious disease agents and calving interval in cattle in the tropics of méxico
IT8235971V0 (it)	1982-07-30	Dispositivo di aspirazione per uso rianimatorio, integrabile in particolare all'attrezzatura per immersione subacquea
ES2033732T3 (es)	1993-04-01	Procedimiento y agente para la arranuela del racimo de la vid eupoecilia ambiquella.
FI981624A7 (fi)	1998-08-05	Koostumukset ja menetelmät Borrelia burgdorferi antigeenien annostelem iseksi